Stock Market & Financial Investment News

News Breaks February 1, 2013 08:06 EDT AMRN Amarin announces notification of additional U.S. patent allowance Amarin Corporation announced that the United States Patent and Trademark Office, or USPTO, has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/272,520 titled "Compositions and Methods for Lowering Triglycerides." This application includes claims intended to protect the proposed Vascepa indication based on Amarin's Phase 3 ANCHOR clinical trial results. Amarin is on track to file a Supplemental New Drug Application for the Vascepa ANCHOR indication with the FDA by the end of February, and expects an FDA action date on the application before the end of 2013. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, after issuance of the patent and approval of Vascepa in the ANCHOR indication. The claims in this allowed application cover a method of use relating to Vascepa's ANCHOR indication. Specifically, the allowed independent claims covers use of about 4 grams per day of highly pure icosapent ethyl, or EPA, including Vascepa, to lower triglycerides and LDL-C. News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 08:04 EDT AMRN Amarin informed by FDA of Oct. 16 advisory committee date for sNDA for Vascepa Subscribe for More Information June 11, 2013 05:56 EDT AMRN Stocks with implied volatility movement; AMRN SODA Stocks with implied volatility movement; Amarin (AMRN), SodaStream (SODA) according to IVolatility. Sign up for a free trial to see the rest of the stories you've been missing.